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REVIEW
Abstract: Cardiovascular disease is a major complication of diabetes mellitus, especially for
patients with diabetic nephropathy. The underlying factor or pathogenic mechanism that links
diabetic nephropathy with cardiovascular disease is not known. The endothelial cell adhesion
molecules, intercellular adhesion molecule-1 or vascular cell adhesion molecule-1, play a
crucial role in the initiation of atherosclerosis. Levels of both cell adhesion molecules are
raised by the diabetic and kidney disease states. This review focuses on these important cell
adhesion molecules and their role in the pathogenesis of cardiovascular disease in diabetes
and diabetic nephropathy.
Keywords: diabetes, kidney disease, cell adhesion
Introduction
Diabetes mellitus (diabetes) affects approximately 100 million people worldwide
(Amos et al 1997). Cardiovascular disease is a major chronic complication of both
type 1 and type 2 diabetes and people with diabetes have an approximately 2–4-fold
increased risk of cardiovascular events, as compared with control populations (Kannel
and McGee 1979; Panzram 1987). In addition to cardiovascular disease, people with
diabetes are also at high risk of developing microvascular complications, the most
clinically important being end-stage kidney disease or diabetic nephropathy.
Importantly, the combination of diabetes and nephropathy increases cardiovascular
disease risk by 20–40-fold (Mattock et al 1992; Alzaid 1996).
Different stages of kidney disease versus
cardiovascular disease risk
Diabetic nephropathy can be classified on its severity. Diabetics initially have no
kidney disease at all. The earliest detectable level of kidney disease is
microalbuminuria, where there is a minute amount of protein that is excreted in the
urine (not detectable by urine dipstick). The next stage is proteinuria, which is defined
as easily measurable levels of protein in the urine, but without disturbance of measures
that generally mark renal failure (creatinine and urea). Lastly, the disease process
may develop into renal failure, otherwise known as uremia (Williams et al 1988;
Iseki et al 2003).
Patients who eventually develop end-stage diabetic renal failure will have passed
through the stages of normal renal function, microalbuminuria, and proteinuria before
reaching uremia. It has long been standard practise to use microalbuminuria as a
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Less clear, until recently, is the role of microalbuminuria as
a marker and therapeutic target in vascular disease
(Anavekar et al 2004).
Albuminuria as a marker for
cardiovascular disease
In the normal population, cardiovascular risk increases in a
continuous fashion along with progression from normal to
overt proteinuria levels (Hillege et al 2001, 2002;
Romundstad et al 2003; Hunsicker et al 2004). Shown in a
prospective 5-year survey of more than 20 000 subjects in
the United Kingdom, microalbuminuria and proteinuria
were independently associated with risk of cardiovascular
disease and death (Romundstad et al 2003). This relationship
is also true for people with diabetes, with post-hoc analyses
of three recent large clinical trials showing that albuminuria
not only determines renal outcomes, but also cardiovascular
outcomes (UKPDS 1998; Anavekar et al 2004; de Zeeuw
et al 2004). In one of these three studies, the reduction of
albuminuria with therapeutic interventions resulted in
protection against cardiovascular disease as well as the
development of progressive renal impairment (UKPDS 1998).
Albuminuria leading to vascular
inflammation
There are many physiological abnormalities that are
attendant in end-stage kidney disease that has led to the
identification of mechanisms that may link cardiovascular
disease and renal failure (Yuyen et al 2004). High on the
list of possible mechanisms are factors such as: hyper-
tension; anemia (Rebelink 2004); dyslipidemia (Rebelink
2004); activation of the renin-angiotensin system (Stevens
and Levin 2003); medial calcification of the vascular tree
(Brewster et al 2003); malnutrition and inflammation
(Brewster et al 2003).
However, while these factors are present in end-stage
nephropathy, not all of them are universally present in the
early stages of albuminuria. Inflammation is associated with
the microalbuminuric state, with albuminuria now
recognized to reflect generalized vascular damage (Hillege
et al 2001). Importantly, inflammation underlies all stages
of atherosclerotic lesion formation, including early
atherogenesis where inflammatory cells adhere and infiltrate
the subendothelium (Liu et al 2004). Critical proteins
expressed by endothelial cells that bind the inflammatory
cells are the cell adhesion molecules (see Figure 1).
Figure 1 Cell adhesion molecules and early atherosclerotic plaque formation. Cell adhesion molecules, including VCAM-1 and ICAM-1, are expressed on the surface
of endothelial cells in response to inflammatory stimuli. Monocytes and other leukocytes bind to the cell adhesion molecules via their own specific cell adhesion
molecules called integrins. Integrin leukocyte function antigen-1 (LFA-1) binds ICAM-1 and very-late antigen-4 (VLA-4) binds VCAM-1 (insert). The binding of the
monocytes to endothelial cells subsequently triggers the tethering, rolling, and subsequent migration of the monocytes into the subintima.
Abbreviations: ICAM-1, intercellular cell adhesion molecule-1; VCAM-1, vascular cell adhesion molecule-1.Vascular Health and Risk Management 2005:1(4) 311
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Cell adhesion molecules,
inflammation, and atherosclerosis
Two important cell adhesion molecules expressed by
endothelial cells that play a major role in the pathogenesis
of atherosclerosis are vascular cell adhesion molecule-1
(VCAM-1) and intercellular cell adhesion molecule-1
(ICAM-1). Expression of both ICAM-1 and VCAM-1 have
been demonstrated in atherosclerotic plaques (Poston et al
1992; Davies et al 1993; Johnson-Tidey et al 1994; O’Brien
et al 1996; DeGraba et al 1998; Blankenberg et al 2003)
with focal expression evident at lesion prone areas (O’Brien
et al 1996; Nakashima et al 1998) and at the borders of
atherosclerotic lesions (Nakashima et al 1998; Iiyama et al
1999). There have been many in vitro studies showing high
glucose milieus increase both ICAM-1 and VCAM-1
endothelial cell expression at both the protein (Kim et al
1994; Baumgartner-Parzer et al 1995; Taki et al 1996;
Takami et al 1998; Manduteanu et al 1999; Esposito et al
2001; Kado et al 2001; Hoffman et al 2002; Omi et al 2002;
Itoh et al 2003) and messenger ribonucleic acid (mRNA)
(Kim et al 1994; Chettab et al 2002; Itoh et al 2003;
Altannavch et al 2004) levels, via a cell signaling mechanism
related to activation of protein kinase C-β (Quagliaro et al
2005). Additionally, human endothelial cells exposed to the
serum of nephropathic patients (none of whom had diabetes)
had high cell surface ICAM-1 and VCAM-1 expression,
correlating with increased mRNA levels (Serradell et al
2002). Our own laboratory has recently shown that exposure
of cultured human endothelial cells to serum from diabetic
patients with advancing stages of diabetic nephropathy
(microalbuminuria progressing to uremia) have a stepwise
increase in the expression of both VCAM-1 and ICAM-1,
as measured at the levels of gene transcription, mRNA, and
protein (Wu et al 2004). This suggests that diabetic/
microalbuminuric patients already have underlying
pathological signaling that increases key early steps in
atherosclerosis using in vitro measures.
Soluble cell adhesion molecules
Although the cell adhesion molecules are firmly anchored
on the cell membranes of endothelial cells, cell adhesion
molecules may be broken off into the circulation forming
soluble VCAM-1 (sVCAM-1) and soluble ICAM-1
(sICAM-1). The underlying physiologic pathway leading
to the formation of soluble cell adhesion molecules and their
subsequent physiologic function remains unclear. Possible
explanations have been proposed, including an increased
synthesis of soluble forms via increased gene transcription,
altered mRNA stability, and/or the existence of alternate
splice variants. However, the favored hypothesis is that
enhanced proteolytic cleavage of the cell adhesion molecules
from the cell surface leads to soluble cell adhesion
molecules, measurable in plasma. This implies that there is
a relationship between the degree of cellular expression of
cell adhesion molecules and plasma soluble cell adhesion
molecule levels. This is yet to be proven. Soluble cell
adhesion molecules are easily measurable in plasma and
much work has been done in the last 10 years on whether
sICAM-1 and sVCAM-1 are useful markers for cardio-
vascular disease in patients with diabetes and diabetic
nephropathy.
Soluble cell adhesion molecules
and diabetic kidney disease
There appears to be a strong relationship between sICAM-
1/VCAM-1 and diabetic nephropathy. A number of studies
have found a general increasing trend in both sICAM-1 and
sVCAM-1 with increasing levels of diabetic kidney disease
in diabetics (Clausen et al 2000; Guler et al 2002; Wu et al
2004). Importantly, sVCAM-1 and sICAM-1 have been
found to be significantly associated with microalbuminuria
in type 2 diabetics as compared with controls (Fasching et
al 1996; Schmidt et al 1996; Gasic et al 1999; Kado and
Nagata 1999; Lim et al 1999; Jager et al 2000; Murakami et
al 2001). This has suggested the potential usefulness of
plasma sVCAM-1 as a marker of vascular perturbation
(Schmidt et al 1996).
Soluble cell adhesion molecules
and diabetic cardiovascular disease
Soluble ICAM-1 and/or sVCAM-1 show good correlation
with cardiovascular disease in diabetic subjects. In a recent
study, type 2 diabetics showed high sICAM-1 levels,
independent of known cardiovascular risks, and predicted
all cause as well as cardiovascular mortality over 10 years
(Becker et al 2002). Increased levels of sVCAM-1 were also
associated with increased risk of mortality in type 2 diabetes,
as seen in the Hoorn study (Jager et al 2000). In the Hoorn
study, 631 type 2 diabetic and control subjects with higher
sVCAM-1 levels at the beginning of the study period had
increased risk of cardiovascular death during 8 years of
follow-up even after adjustment for age, sex, glucose
tolerance, hypertension, cardiovascular disease, high density
lipoproteins, low density lipoproteins, homocysteine,Vascular Health and Risk Management 2005:1(4) 312
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levels have been demonstrated to be predictive for the future
development of cardiovascular disease and mortality in
diabetic subjects.
Correlations with novel risk
factors for atherosclerosis
The cell adhesion molecules are just one of a number of
emerging markers for cardiovascular risk factors (Table 1).
Additional to cell adhesion molecules, one of the most
exciting novel risk factors sparking a lot of research interest
is C-reactive protein. The significance of C-reactive protein
and inflammation has become increasingly evident recently,
and it now appears that C-reactive protein actively
contributes to atherosclerotic plaque formation and throm-
botic events. Additionally, C-reactive protein is associated
with the inflammatory states of not only renal failure, but
also microalbuminuria. In a recent study, C-reactive protein
was found to be associated with cardiovascular mortality
risk rate in patients with end-stage kidney disease, and
traditional risk factors including left ventricular hypertrophy
Figure 2 sVCAM-1 and sICAM-1. VCAM-1 and ICAM-1 are expressed on the cell surface of cells. Soluble forms of VCAM-1 and ICAM-1 are measurable in plasma.
Several theories for the formation of the soluble forms exist, including alternate splicing, increased transcription, and proteolytic cleavage of the membrane protein
(favored). There is an increase in sVCAM-1 and ICAM-1 in plasma of diabetic patients associated with an increase in the severity of kidney disease.
Abbreviations: ICAM-1, intercellular cell adhesion molecule-1; VCAM-1, vascular cell adhesion molecule-1; sICAM-1, soluble intercellular adhesion molecule-1;
sVCAM-1, soluble vascular cell adhesion molecule-1.
microalbuminuria, von Willebrand factor, C-reactive protein,
and glomerular filtration rate. The effect was magnified in
type 2 diabetics, thus indicating that sVCAM-1 is
independently associated with the risk of cardiovascular
mortality (Jager et al 2000). In another study, Stehouwer et
al (2002) also showed that high sVCAM-1 levels were
independently associated with increased mortality in type 2
diabetics followed for a mean of 9 years.
These findings are well supported by a number of cross-
sectional studies. Both sICAM-1 and sVCAM-1 levels were
higher in elderly type 2 diabetics with known cerebro-
vascular disease (Kawamura et al 1998); and sVCAM-1
levels were higher in type 2 diabetic patients with
symptomatic cardiovascular disease as compared with those
with no known cardiovascular disease (Otsuki et al 1997).
However, one very recent study did not demonstrate any
correlation between sICAM-1, sVCAM-1, and known
cardiovascular disease, nor with degree of intimamedia
thickening (Leinonen et al 2003). It is important to keep in
mind that this last survey was smaller than the longitudinal
studies outlined above. Overall, sICAM-1 and sVCAM-1Vascular Health and Risk Management 2005:1(4) 313
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showed higher associations (Shlipak et al 2005). Similarly,
in cell adhesion molecules, recent data reported a linear
association between the level of albuminuria and elevations
of C-reactive protein. Specific monitoring has been proposed
(Bakris 2004). C-reactive protein studies remain in their
infancy and prognostic values remain on a case-by-case basis
(McCullough 2004). Both sICAM-1 (Ridker et al 1998) and
sVCAM-1 (Schalkwijk et al 1999; Jager et al 2000) levels
have been shown to significantly correlate with C-reactive
protein in the diabetic setting.
The soluble cell adhesion molecules also associate with
other prominent novel cardiovascular risk factors including
carotid intimamedia thickness (Otsuki et al 1997; Kawamura
et al 1998; Matsumoto et al 2002; Takeuchi et al 2002),
advanced glycation end-points (Smulders et al 1998;
Vlassara et al 2003; Lieuw et al 2004), plasma von
Willebrand factor and homocysteine (Ridker et al 1998;
Jager et al 2000; Targher et al 2001), fibrinogen, and tissue-
type plasminogen-activator antigen (Ridker et al 1998),
thereby justifying their consideration as a novel risk marker
for cardiovascular disease, especially in diabetic patients.
The effect of treatments on
sICAM-1 and sVCAM-1
The effect of glucose control on sICAM-1 and sVCAM-1
is not consistent between studies, with only a minority
showing decreasing soluble cell adhesion molecule levels
with normalization of glucose (Albertinin et al 1998;
Marfella et al 2000). However, diet and dietary supplements
can influence soluble cell adhesion molecule levels; eg,
ingestion of antioxidants vitamins E and C immediately after
a meal can significantly suppress the rapid rise in sICAM-1
and sVCAM-1 seen with a high fat meal (Nappo et al 2002).
Additionally, diabetics given RRR-alphatocopheol therapy
for 3 months showed a significant fall in sVCAM-1 and
sICAM-1 (Devaraj and Jialal 2000). Other antioxidants have
also been shown to decrease cell adhesion molecules in
type 2 diabetics, such as N-acetyl-L-cysteine which
decreased sVCAM-1 (De Mattia et al 1998) and glutathione
which decreased sICAM-1 (Ceriello et al 1998).
Pharmacologic treatments can also effect soluble cell
adhesion molecule levels; eg, hypertension is a common
problem in diabetics and blockade of the renin-angiotensin
system is a common method to achieve control of blood
pressure. The angiotensin-converting enzyme inhibitor,
fosinopril, administered for 12 weeks to microalbuminuric
type 2 diabetics, decreased sVCAM-1 to control levels, but
did not change sICAM-1 levels (Gasic et al 1999). In a
crossover trial in type 2 diabetics, angiotensin-converting
enzyme inhibitor, enalapril, and angiotensin receptor II
blocker, losartan, both decreased sVCAM-1, but not
sICAM-1 (Andersen et al 2000). Even though both
decreased blood pressure and urine albumin excretion by
the same amount, the enalapril was found to be more
effective than losartan in decreasing the level of sVCAM-1
(Andersen et al 2000). In another example, management of
dyslipidemia with hydroxymethyl glutaroyl coenzyme A
(HMG-coA) reductase inhibitors (statins) is also common
in diabetes. Three months of simvastatin therapy was able
to significantly decrease both sICAM-1 and sVCAM-1
levels (Ceriello et al 2004). In addition, simvastatin was able
to significantly suppress the acute rise in sICAM-1 and
sVCAM-1 seen after a glucose load and/or high-fat oral
load (Ceriello et al 2004). A similar drug, atorvastatin,
significantly decreased sVCAM-1 in type 2 diabetics as
compared with placebo (Dalla Nora et al 2003). Cardio-
vascular patients are often treated with antiplatelet agents,
including aspirin and sarpogrelate. Both these drugs have
been found to decrease serum sICAM-1 levels (Shouzu et
al 2000; Mateos-Careres et al 2002). Lastly, hormone
replacement therapy is often used by older women to control
the symptoms of menopause and until recently, was thought
to have cardioprotective benefit, although this is now very
controversial (Prentice et al 2005). Hormone replacement
Table 1 Association of kidney disease with risk factors for
cardiovascular disease







Nontraditional cardiovascular disease risk factors
Elevated c-Reactive protein
Elevated von Willebrand factor




Absent nocturnal drop in blood pressure
Insulin resistance
Elevated white blood cell count
Prolonged Q-T interval
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therapy, whether oestrogen only (Koh et al 2001), or
combined oestrogen-progestin based (Manning et al 2002),
did not have any effect on sICAM-1 or sVCAM-1 levels in
post-menopausal type 2 diabetic women.
In summary, dietary interventions and some medications
lower sVCAM-1 and sICAM-1 levels. Therefore cell
adhesion molecules could be considered adjunctive factors
to monitor, especially in diabetic and diabetic nephropathy
patients, as a dual measure of cardiovascular and kidney
disease risk.
Summary
The prevalence of cardiovascular disease in diabetic
nephropathy patients is high and is a major cause of
morbidity and mortality. The cell adhesion molecules,
ICAM-1 and VCAM-1, are raised in both cardiovascular
disease and diabetic nephropathy, with levels increasing
in stepwise fashion with increasing kidney disease.
Importantly, sICAM-1 and sVCAM-1 levels are raised even
in the earliest stage of diabetic kidney disease; micro-
albuminuria. They are good predictors of atherosclerotic
disease and cardiovascular mortality, and they correlate well
with other conventional and nonconventional risk factors.
sICAM-1 and sVCAM-1 are lowered by some dietary
supplements and pharmacologic agents and therefore
represent factors that can be measured to correlate with
decreased cardiovascular risk, although more prospective
correlative studies would be required for their use as a
primary strategy. As early detection of renal impairment and
cardiovascular disease in the type 2 diabetic remains a global
health priority, soluble cell adhesion molecules may
represent a marker of vascular disease, associated closely
with early diabetic kidney disease, which if monitored could
allow patients to have significant benefit from both reno-
and cardioprotective treatment.
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